The study of transitioning from alendronate to denosumab (STAND) evaluated the impact on safety, BMD, and bone remodeling in patients switching from alendronate to denosumab (Kendler et al

The study of transitioning from alendronate to denosumab (STAND) evaluated the impact on safety, BMD, and bone remodeling in patients switching from alendronate to denosumab (Kendler et al. transverse femoral shaft fracture with lateral cortical hypertrophy and medial spiking. The fracture was stabilized with a cephalomedullary nail. Routine blood investigations were within normal range and myeloma was excluded. Mouse Monoclonal to beta-Actin Bone densitometry revealed an increase in bone density relative to baseline values before the initiation of alendronate therapy, but the T-score of at least 1 site was still in the osteoporotic range (femoral neck T-score: C2.95). 5 months postoperatively, the fracture had healed with callus formation. 1 year after the first fracture, the patient sustained a similar atypical fracture of the right femoral shaft (Figure 2) and she described mild, diffuse pain in the thigh during the previous 6C7 months. She was still on treatment with denosumab 12 months after the first injection (she had received 3 injections of denosumab at 6-month intervals). This fracture was also stabilized with a cephalomedullary nail and a pathological fracture was excluded. Open in a separate window Figure 2. Both femurs at the time of the right femoral shaft fracture. This fracture also healed in 5 months with callus formation (Figure 3). In view of reports linking this pattern of femoral shaft fractures to long-term alendronate therapy (Neviaser et al. 2008) and considering the anti-resorptive mechanism of action of the denosumab, treatment with teriparatide (20 g subcutaneously once a day) and vitamin D was commenced and denosumab was stopped. Open in a separate window Figure 3. Anteroposterior radiograph of both femurs 5 months after the second operation, showing healing of the fracture with callus formation. Discussion In recent years, several clinical case reports and case reviews have described atypical femoral fractures (AFFs) in patients receiving treatment with biphosphonates. It has been hypothesized that suppression of bone turnover leads to accumulation of microdamage and an increased risk of AFF (Shane et al. 2013) with prolonged bisphosphonate exposure. The American Society for Bone and Mineral Research (ASBMR) task force described major and minor defining features of AFF (Shane et al. 2013). Our case had Crenolanib (CP-868596) all of the major features: the location was the subtrochanteric region, the fracture was transverse, there was no trauma, there was a medial spike, there was no comminution, and there was a periosteal reaction of the lateral cortex. Regarding the minor features, there was cortical thickening, prodromal pain, and bilaterality. We have found only 1 1 reported case of an unusual subtrochanteric fracture in a patient on denosumab (Paparodis et al. 2013). Denosumab offers an alternative approach to the treatment of osteoporosis. It is a fully human monoclonal antibody to the receptor activator of nuclear factor-B ligand (RANKL) that prevents the interaction of RANKL with RANK (its receptor on osteoclasts and their precursors), thereby blocking the formation, function, and survival of osteoclasts (Cummings et al. 2009). The study of transitioning from alendronate to denosumab (STAND) evaluated the impact on safety, BMD, and bone remodeling in sufferers switching from alendronate to denosumab (Kendler et al. 2010) and contributed to FDA acceptance of denosumab. The chance of AFFs seems to upsurge in parallel using the duration of bisphosphonate publicity, from 1.8 cases per Crenolanib (CP-868596) 105 users each year of publicity for the first 24 months, to 113 cases per 105 users each year at 8 many years of bisphosphonate use (Kendler et al. 2010). Our affected individual developed her initial fracture after 8 many years of alendronate make use of. Furthermore, regarding to Schilcher et al. (2011), after medication drawback, bisphosphonate-associated risk diminishes by 70% each year because the last make use of. The initial fracture inside our affected individual occurred 3 weeks after last make use of simply, so there may be a solid association with biphosphonates and a causal romantic relationship is highly most likely. The next fracture happened 12 months and 3 weeks following the last usage of biphosphonate, therefore within this whole case the causal relationship is unlikely to can be found. Our affected individual acquired received the initial shot of denosumab a week before the initial fracture and she received 2 various other dosages prior to the second fracture (to the proper femur) i.e. she acquired subcutaneous administration of 60 mg denosumab every six months. The limited period of contact with denosumab prior to the initial fracture helps it be unlikely that fracture was causally linked to the consequences of denosumab, but by enough time of the next fracture a calendar year later the individual have been subjected to 3 dosages of denoumab. The efficiency and basic safety of pharmacological treatment (e.g. teriparatide, strontium ranelate, denosumab) for sufferers with osteoporosis continues to be a location for analysis, but since over-suppression of bone Crenolanib (CP-868596) tissue turnover.